---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-24-020010"
form_type: "8-K"
ticker: "CRDF"
cik: "0001213037"
company_name: "Cardiff Oncology, Inc."
filed_at: "2024-05-02T23:59:59+00:00"
generated_at: "2026-06-02T23:58:24.642318+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Cardiff Oncology Q1 2024: $67.2M cash, ONSEMBLE data show 50% ORR in bev naïve mCRC

## Summary
- Cash and equivalents $67.2M as of March 31, 2024; projected runway into Q3 2025.
- Operating expenses $11.1M, down $1.0M YoY; net cash used in ops $7.7M.
- ONSEMBLE trial: bev naïve patients on onvansertib+SoC had 50% ORR vs 0% for SoC alone.
- Initial readout from first-line RAS-mutated mCRC Phase 2 CRDF-004 trial expected 2H 2024.
- Preclinical AACR data showed onvansertib activity in RAS wild-type mCRC, SCLC, and ovarian cancer.

## SEC filing metadata
- accession: 0001628280-24-020010
- form_type: 8-K
- ticker: CRDF
- cik: 0001213037
- company_name: Cardiff Oncology, Inc.
- filed_at: 2024-05-02T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1213037/000162828024020010/0001628280-24-020010-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1213037/000162828024020010/crdf-20240502.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-24-020010
- JSON: https://secwatch.observer/filing/0001628280-24-020010.json
- Plain text: https://secwatch.observer/filing/0001628280-24-020010.txt

## Key facts
- Earnings Releases
  Cardiff Oncology, Inc. reported financial results for first quarter ended March 31, 2024.
  - Period: first quarter ended March 31, 2024
  - Result: reported results
  source text: On May 2, 2024, Cardiff Oncology, Inc. issued a press release announcing company highlights and financial results for the first quarter ended March 31, 2024 .
  evidence_url: https://www.sec.gov/Archives/edgar/data/1213037/000162828024020010/0001628280-24-020010-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.